Croatian National Data and Comparison with European Practice: Data from the Cardiac Resynchronization Therapy Survey II Multicenter Registry
Table 1
Baseline characteristics and preprocedural data of Croatian CRT population and comparison with the European population.
Croatia
Europe
value
OR (95% CI)
Demographics
Age
66.1 ± 11.0
68.6 ± 10.8
0.017
Men
78.8 (89/113)
75.7 (8277/10939)
0.445
BMI
28.1 ± 4.2
27.9 ± 5.0
0.162
History
Hypertension
75.2 (85/113)
63.8 (6877/10787)
0.012
1.73 (1.12–2.65)
Diabetes mellitus
30.1 (34/113)
31.4 (3394/10808)
0.765
Obstructive lung disease
8.8 (10/113)
12.1 (1305/10809)
0.295
Atrial fibrillation
33.6 (38/113)
40.9 (4421/10807)
0.117
Paroxysmal
28.9 (11/38)
34.8 (1537/4421)
0.344
Persistent
21.1 (8/38)
22.3 (986/4421)
Permanent
50.0 (19/38)
42.3 (1870/4421)
Chronic kidney disease (<60)
26.5 (30/113)
31.2 (3365/10794)
0.291
Prior revascularization (CABG or PCI)
50.4 (57/113)
75.3 (8145/10813)
0.006
0.56 (0.36–0.86)
HF hospitalisation during last year
46.0 (52/113)
46.5 (5026/10804)
0.915
Prior device (PPM, ICD)
13.3 (15/113)
28.0 (3044/10879)
<0.001
0.39 (0.23–0.68)
Primary HF aetiology
0.477
Ischaemic
38.1 (43/113)
44.6 (4832/10840)
Nonischaemic
61.1 (69/113)
49.7 (5384/10840)
Others
0.9 (1/113)
5.8 (624/10840)
ECG
Heart rate (beats/min)
76 ± 19
72 ± 16
0.028
Sinus rhythm
76.1 (86/113)
69.1 (7410/10723)
0.071
Atrial fibrillation
23.0 (26/113)
25.7 (2752/10723)
PR interval (ms)
182 ± 47
189 ± 50
0.337
AV block II or III
15.0 (17/113)
19.0 (2009/10587)
0.289
QRS duration (ms)
154 ± 24
157 ± 27
0.436
QRS duration <120 ms
8.3 (9/108)
7.4 (702/9427)
QRS duration 120–130 ms
5.6 (6/108)
5.3 (499/9427)
QRS duration 130–150 ms
18.5 (20/108)
18.7 (1759/9427)
QRS duration 150–180 ms
48.1 (52/108)
47.0 (4434/9427)
QRS duration >180 ms
19.4 (21/108)
21.6 (2033/9427)
QRS morphology
LBBB
80.0 (88/110)
75.2 (7750/10307)
0.245
RBBB
8.2 (9/110)
6.6 (679/10307)
0.503
Others
11.8 (13/110)
18.2 (1878/10307)
0.083
CRT indication
Heart failure with wide QRS
73.5 (83/113)
59.8 (6467/10810)
0.003
1.86 (1.22–2.83)
HF or LV dysfunction and an indication for ICD
27.4 (31/113)
48.1 (5197/10810)
0.001
0.41 (0.27–0.62)
PM indication + expected pacing dependency
21.2 (24/113)
22.8 (2470/10810)
0.685
Evidence of medical dyssynchrony
4.4 (5/113)
11.6 (1255/10810)
0.018
0.35 (0.14–0.87)
Clinical evaluation
0.158
NYHA I
0.0 (0/112)
3.4 (370/10736)
NYHA II
48.2 (54/112)
37.5 (4029/10736)
NYHA III
50.0 (56/112)
54.5 (5853/10736)
NYHA IV
1.8 (2/112)
4.5 (484/10736)
Echocardiography
Mean LV ejection fraction (%)
29.1 ± 7.3
28.4 ± 8.2
0.314
<35%
74.3 (84/113)
76.6 (8198/10692)
35–50%
25.6 (29/113)
21.5 (2299/10692)
>50%
0.0 (0/113)
1.8 (195/10692)
LV end-diastolic diameter (mm)
65.6 ± 8.5
63.5 ± 9.1
0.039
Mitral regurgitation
<0.001
Mild
39.2 (40/102)
46.5 (4604/9898)
0.74 (0.50–1.11)
Moderate
50.0 (51/102)
26.2 (2595/9898)
2.81 (1.90–4.16)
Severe
7.8 (8/102)
6.9 (682/9898)
1.15 (0.56–2.38)
None
2.9 (3/102)
20.4 (2017/9898)
0.12 (0.04–0.37)
Laboratory results
NT-pro BNP (pg/mL)
3447.5 ± 3270.8
5111.8 ± 8144.1
0.725
Hemoglobin (g/L)
13.6 ± 1.6
13.3 ± 1.8
0.079
Creatinine (μmol/L)
107.1 ± 36.7
114.1 ± 65.9
0.417
Values are % () for categorical and mean ± standard deviation or median (25th–75th percentile) for continuous variables. BMI: body mass index; CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention; HF: heart failure; PPM: permanent pacemaker; ICD: implantable cardioverter-defibrillator; LBBB: left bundle branch block; RBBB: right bundle branch block; LV: left ventricle; BNP: brain-type natriuretic peptide. ∗NT-pro BNP was measured only in 18 patients in Croatia (15.6% of patients).
